Q-omics provides the consensus-scored COCH profile across patient tissues and cancer cell-line models. COCH expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, COCH is differentially expressed in 16, with the highest sampling consensus in LUAD. Additionally, COCH RNA expression shows 16,023 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUAD as cancer lineages where COCH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COCH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COCH survival associations across molecular data types. COCH RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COCH RNA expression–survival associations across cancer types. High COCH expression shows unfavorable associations in UVM, STAD, ACC and KIRC, but favorable associations in LUSC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for COCH RNA expression.
This table summarizes COCH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COCH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COCH shows lower tumor expression in KIRC and THCA and higher tumor expression in LUAD, LIHC, HNSC and LUSC. The LUAD box plot shows higher COCH RNA expression in tumor versus normal tissue (log2 FC = +2.871, t-test p < 0.001).
This table shows molecular features associated with COCH in patient tissues and cancer cell lines. In patient samples, COCH shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, COCH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
